Abd M. Ismaiel
VCU Medical Center
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Abd M. Ismaiel.
European Journal of Pharmacology | 1989
Richard A. Glennon; Abd M. Ismaiel; Bruce M. McCarthy; Stephen J. Peroutka
The binding affinities of a series of arylpiperazine derivatives at [3H]quipazine-labeled central 5-HT3 sites were investigated. Features determined to be important for binding include the N4 piperazine nitrogen atom (but not the N1 piperazine nitrogen), and a quinolinyl group. The quinoline nitrogen atom of quipazine also contributes to affinity and its replacement by carbon reduces affinity by 20-fold. The entire quinoline nucleus is not necessary for binding, and certain monocyclic arylpiperazines, particularly those with a chloro group meta to the position of the piperazine ring (e.g. mCPP, MK-212), also bind at 5-HT3, sites; however, the affinities of these agents are at least an order of magnitude less than that of quipazine itself. Taking advantage of the fact that tertiary amines are not well tolerated at 5-HT1B sites, but that N-methyl substituents have little effect on 5-HT3 binding, we designed and synthesized a tertiary amine analog of quipazine, i.e., N-methylquipazine (NMQ). NMQ binds at 5-HT3 sites with an affinity similar to that of quipazine; however, unlike quipazine, NMQ shows very little affinity (IC50 greater than 10,000 nM) for central 5-HT1B sites.
Current Topics in Medicinal Chemistry | 2002
Richard A. Glennon; Kamel Metwally; Małgorzata Dukat; Abd M. Ismaiel; Joseph De. Los Angeles; Jeffery Herndon; Milt Teitler; Nantaka Khorana
The structures of ketanserin (1) and spiperone (2) were examined in detail to determine the role of various substituent groups on 5-HT(2A) receptor affinity and selectivity. It was found that the presence of the quinazoline ring of ketanserin detracts from selectivity and that various ring-opened analogs displayed ketanserin-like affinity and up to 30-fold enhanced selectivity. The triazaspirodecanone portion of spiperone is a major determinant of its 5-HT affinity and selectivity. The conformational rigidity imposed by the ring, as well as the nature of the N(1)-substituent, are important factors in controlling binding at 5-HT(2A), 5-HT(2C), 5-HT(1A), and dopamine D2 receptors. Replacement of the N(1)-phenyl ring of spiperone with a methyl group (KML-010; 48) resulted in a compound that binds at 5-HT(2A) receptors with slightly lower affinity than spiperone, but that lacked affinity (Ki >10,000 nM) for 5-HT(2C) and 5-HT(1A) receptors and binds with 400-fold reduced affinity at D2 receptors.
Pharmacology, Biochemistry and Behavior | 1988
Richard A. Glennon; Abd M. Ismaiel; Billy R. Martin; Douglas Poff; Michael A Sutton
The controlled-substance analog N-monomethyl-1-(4-methoxyphenyl)-2-aminopropane (PMMA) may be viewed as being either the 4-methoxy analog of methamphetamine or the N-methyl analog of 1-(4-methoxyphenyl)-2-aminopropane (PMA). Because of its abuse potential, PMMA was examined with regard to (a) its stimulus properties in rats trained to discriminate either 1.0 mg/kg of (+)amphetamine or (+/-)DOM from saline, (b) its toxicity (isolated and aggregated) in mice relative to (+/-)PMA, and (c) its locomotor stimulant activity in mice relative to (+/-)amphetamine, (+/-)methamphetamine, and (+/-)PMA. Racemic PMMA produced neither DOM-like nor, unlike PMA, amphetamine-like stimulus effects. There was no significant difference between the 24-hr isolated (LD50 = 63 mg/kg) and aggregated (LD50 = 53 mg/kg) toxicity, and PMMA did not produce significant locomotor stimulation at doses of up to 30 mg/kg. The present results suggest that while PMMA may produce central effects it does not appear to behave as a simple amphetamine-like agent.
Journal of Medicinal Chemistry | 1992
Jeff L. Herndon; Abd M. Ismaiel; Stacy P. Ingher; Milt Teitler; Richard A. Glennon
Journal of Medicinal Chemistry | 1994
Richard A. Glennon; Seth Y. Ablordeppey; Abd M. Ismaiel; Mahmoud El-Ashmawy; James B. Fischer; Kathleen J. Burke Howie
Journal of Medicinal Chemistry | 1990
Abd M. Ismaiel; Milt Titeler; Keith J. Miller; Thomas S. Smith; Richard A. Glennon
Brain Research | 1990
Laura Rydelek-Fitzgerald; Milton Teitler; Paul W. Fletcher; Abd M. Ismaiel; Richard A. Glennon
Journal of Medicinal Chemistry | 1996
Małgorzata Dukat; Ashraf A. Abdel-Rahman; Abd M. Ismaiel; Stacy P. Ingher; Milt Teitler; Laszlo Gyermek; Richard A. Glennon
Journal of Medicinal Chemistry | 1989
Richard A. Glennon; Noreen Naiman; Pierson Me; Smith Jd; Abd M. Ismaiel; Milt Titeler; Robert A. Lyon
Journal of Medicinal Chemistry | 1995
Abd M. Ismaiel; Kim Arruda; Milt Teitler; Richard A. Glennon